Related by context. All words. (Click for frequent words.) 76 PSADT 76 PSA nadir 76 radical prostatectomy RP 75 preoperative PSA 75 clinically localized prostate 75 biochemical relapse 75 seminal vesicle invasion 74 #.#ng/ml 74 pT3 74 locoregional recurrence 74 PCa 74 pCR 74 preoperative chemotherapy 73 postoperative mortality 73 lymphadenectomy 73 distant metastasis 72 distant metastases 72 P = .# 72 advanced adenoma 72 neoadjuvant therapy 72 Kaplan Meier 72 CR nPR 72 perioperative mortality 71 prostate cancer CaP 71 androgen deprivation 71 cystectomy 71 endometrial carcinoma 71 specific antigen PSA 71 EBRT 71 lymph node metastasis 71 radical prostatectomy 71 extracapsular extension 71 Kaplan Meier analysis 71 progression TTP 71 F FDG PET 71 locoregional 71 intact parathyroid hormone 71 underwent resection 70 advanced neoplasia 70 neoadjuvant chemotherapy 70 radical nephrectomy 70 tumor recurrence 70 renal tumors 70 serum PSA 70 radical cystectomy 70 NMIBC 70 median PFS 70 oncologic outcomes 70 nodal metastases 70 advanced adenomas 70 CIN2 + 70 CIN3 70 tumor histology 70 pT2 69 postoperative complication 69 lymph node involvement 69 SUVmax 69 HER2 expression 69 radiotherapy RT 69 FDG uptake 69 ischemic lesions 69 LV dysfunction 69 operable breast cancer 69 HNSCC 69 serum testosterone 69 carotid stenosis 69 Radical prostatectomy 69 hip BMD 69 univariate analysis 69 histologic 69 MACCE 68 postintervention 68 multivariable analysis 68 prognostic variables 68 perioperative complications 68 % CI #.#-#.# [003] 68 % Confidence Interval 68 adenoma recurrence 68 MMSE score 68 adjuvant radiotherapy 68 histologic subtype 68 clinicopathological features 68 univariate analyzes 68 androgen suppression 68 definite stent thrombosis 68 neoadjuvant 68 colorectal adenoma 68 atypical hyperplasia 68 undergoing radical prostatectomy 68 atheroma volume 68 nonfatal MI 68 breast carcinoma 68 multivariate analyzes 68 posttreatment 68 sleeve lobectomy 68 multivariate Cox 68 prostate carcinoma 68 lymph node metastases 68 rebleeding 68 prostatectomy 68 SLNB 68 nodal metastasis 68 lymphocytosis 68 tumor resection 67 intima media thickness 67 Kaplan Meier estimates 67 coronary revascularization 67 hepatocellular carcinomas 67 hepatic resection 67 p = #.# [003] 67 T1a 67 chemoradiotherapy 67 binary restenosis 67 curative resection 67 histological subtype 67 lymphovascular invasion 67 confidence intervals CIs 67 underwent surgical resection 67 reoperation 67 XIENCE V PROMUS Stent 67 nephron sparing surgery 67 R0 resection 67 SCr 67 recurrent VTE 67 lowest tertile 67 Median progression 67 Operative mortality 67 urothelial carcinoma 67 adenoma 67 ovarian carcinoma 67 pelvic lymphadenectomy 67 undetectable PSA 67 biopsy Gleason 67 BRCA2 mutation carriers 67 gadolinium enhanced 67 completely resected 67 resected 67 pancreatic adenocarcinoma 67 prognostic factor 67 FOLFOX4 67 troponin T 67 adjuvant chemotherapy 67 undetectable HBV DNA 67 nonmetastatic 67 postoperative morbidity 67 adenomatous polyps 67 LVEF 66 reintervention 66 confidence interval #.#-#.# 66 malignant neoplasm 66 nephrectomy 66 serum creatinine levels 66 prospectively defined 66 liver metastasis 66 reinfarction 66 cytoreductive nephrectomy 66 prognostic factors 66 thyroglobulin 66 histologically 66 axillary lymph nodes 66 cytoreductive surgery 66 virologic response 66 TRUS 66 elevated LDH 66 perioperative morbidity 66 thyroid carcinoma 66 univariate 66 response pCR 66 periprocedural 66 mediastinal 66 FDG PET 66 MetS 66 external beam radiotherapy 66 Subgroup analyzes 66 debulking surgery 66 esophagectomy 66 Flu Cy 66 resectable 66 HGPIN 66 transurethral resection 66 perioperatively 66 ALND 66 liver histology 66 ipsilateral stroke 66 hematologic toxicity 66 % CI #.#-#.# [007] 66 baseline LDH 66 serum prostate 66 lymph node dissection 66 ultrasonographic 66 virologic failure 66 posttransplant 66 eGFR 66 asymptomatic carotid stenosis 66 pg mL 66 Median survival 66 HbA 1c levels 66 TURBT 66 carotid IMT 66 preoperatively 66 Kaplan Meier method 66 thromboembolic events 66 invasive ductal 66 cytoreduction 66 HBeAg seroconversion 65 contralateral breast cancer 65 platelet reactivity 65 gastric adenocarcinoma 65 orchiectomy 65 mL/min/#.# m 2 65 HRQOL 65 femoral neck fracture 65 revascularization procedures 65 MADRS score 65 Logistic regression 65 CR CRu 65 NIHSS score 65 adrenalectomy 65 nondiabetic patients 65 colorectal neoplasia 65 coronary stenosis 65 mucinous 65 chlorambucil 65 highest tertile 65 CCyR 65 endometrial thickness 65 EDSS scores 65 graft dysfunction 65 axillary lymph node 65 microsatellite instability 65 radical retropubic prostatectomy 65 undergone radical prostatectomy 65 underwent radical prostatectomy 65 differentiated thyroid 65 logistic regression analysis 65 estimated glomerular filtration 65 mg kg dose 65 p = .# [002] 65 postoperative chemotherapy 65 EDSS score 65 ALT elevation 65 NIHSS 65 T2 lesions 65 Kaplan Meier curves 65 angiographic restenosis 65 nonmetastatic prostate cancer 65 pneumonectomy 65 axillary dissection 65 Subgroup analysis 65 pulmonary metastases 65 Stent thrombosis 65 5-fluorouracil/leucovorin 65 sustained virological response 65 prognostic indicator 65 intravesical therapy 65 hsCRP levels 65 conditional logistic regression 65 polyp recurrence 65 TURP 65 symptomatic VTE 65 T1c 65 arterial thickening 65 partial nephrectomy 65 cTnT 65 esophageal carcinoma 65 vertebral fracture 65 FDG-PET/CT 65 plain radiographs 65 liver transplant recipients 65 contralateral breast 65 node metastases 65 virological response 65 μmol L 65 liver resection 65 carcinoids 65 micrometastases 65 adjuvant therapy 65 postoperative radiotherapy 65 neoplasm 65 grade cervical intraepithelial 65 subtrochanteric 65 radiochemotherapy 65 adjuvant therapies 65 secondary efficacy endpoint 65 HOMA IR 65 relapsed MM 65 lobectomy 65 paclitaxel eluting stents 64 castrate resistant 64 p = NS 64 ASCUS 64 multivariable adjusted 64 prostate biopsy 64 intestinal metaplasia 64 timepoints 64 precursor lesions 64 thyroid nodules 64 Prostate specific antigen 64 % CI #.#-#.# [006] 64 histologically confirmed 64 obstructive coronary artery 64 bladder carcinoma 64 nonfasting triglyceride levels 64 concurrent chemoradiation 64 Partial Responses 64 noncardiac 64 prostate cancer PCa 64 genotypic resistance 64 myocardial infarction MI 64 nonfatal myocardial infarction 64 adenomatous 64 leukocyte count 64 ng dL 64 pmol L 64 death reinfarction 64 KRAS mutations 64 KRAS mutations occur 64 RALP 64 imatinib therapy 64 5-FU/LV 64 confidence interval CI 64 angiographically 64 alanine aminotransferase ALT 64 adnexal mass 64 PASI scores 64 Free Survival PFS 64 MGUS 64 glycated hemoglobin levels 64 macroalbuminuria 64 HbA 1c 64 serum testosterone levels 64 HbA1C levels 64 echocardiographic 64 urinary N telopeptide 64 postop 64 mg/m2 dose 64 femoral neck BMD 64 CTEPH 64 antibody titer 64 progesterone receptor negative 64 lumbar spine BMD 64 GnRH agonist 64 stage IIIB 64 tertile 64 Secondary endpoints included 64 micrometastasis 64 HER2 negative 64 non squamous NSCLC 64 mRS 64 interobserver reliability 64 pancreatic resection 64 multivariate logistic regression 64 tPSA 64 localized renal 64 colorectal liver metastases 64 KRAS wild 64 lung metastasis 64 colorectal carcinoma 64 clinicopathological 64 nonobstructive CAD 64 axillary node dissection 64 pericardial effusion 64 radiographic progression 64 XIENCE V demonstrated 64 malignant lesions 64 CaP 64 Histologic 64 HSCT 64 detectable HCV RNA 64 cerebral infarction 64 ischemic cardiomyopathy 64 intraobserver 64 prognostic significance 64 radioiodine therapy 64 colorectal carcinomas 64 FOLFIRI alone 64 clodronate 64 transthoracic 64 colorectal adenomas 64 sensitivity specificity 63 IV NSCLC 63 stage IIIb IV 63 sentinel lymph node biopsy 63 recurrent venous thromboembolism 63 pretest probability 63 pathologic 63 KRAS mutation 63 hepatic metastases 63 diabetes mellitus DM 63 Partial Response 63 metastatic malignant melanoma 63 retrospective cohort 63 serum concentrations 63 KRAS status 63 FOLPI 63 microalbuminuria 63 prostatic adenocarcinoma 63 adenotonsillectomy 63 axillary node 63 Recurrence Score 63 free survival PFS 63 thymoma 63 metastatic RCC 63 nonoperative treatment 63 colorectal neoplasms 63 spirometric 63 metastatic disease 63 mRNA expression 63 logistic regression model 63 hepatectomy 63 Response Evaluation Criteria 63 Hb A1C 63 rs# [002] 63 adjuvant radiation 63 metastatic lesions 63 serum HCV RNA 63 preintervention 63 median survivals 63 glomerular filtration rate 63 HbA1c levels 63 albumin excretion 63 TAVR 63 octreotide LAR 63 ICD implantation 63 malignant pleural mesothelioma 63 mRCC 63 myocardial viability 63 postoperative pulmonary 63 cTnI 63 Logistic regression analysis 63 neurodevelopmental impairment 63 Doxil ® 63 chemoradiation therapy 63 neoplasia 63 hip resurfacing arthroplasty 63 prostate adenocarcinoma 63 bone metastasis 63 histopathological 63 albumin excretion rate 63 aminotransferase levels 63 femoral shaft fracture 63 sustained virologic response 63 HBeAg negative 63 CIN2 63 QRS duration 63 pg ml 63 A1c levels 63 virologic responses 63 HER2 amplification 63 mammographic density 63 VcMP 63 CVD mortality 63 recanalization 63 endosonography 63 GISTs 63 beta blocker therapy 63 renal artery stenosis 63 SGRQ 63 NYHA functional class 63 urine cytology 63 metastatic renal cell carcinoma 63 hematopoietic cancers 63 MMSE scores 63 endovascular repair 63 aminotransferases 63 % CI #.#-#.# [008] 63 symptomatic intracerebral hemorrhage 63 surgical debulking 63 PNH patients 63 transaminase levels 63 multivariable analyzes 63 PCA3 scores 63 metachronous 63 PSA kinetics 63 epithelial tumors 63 coronary calcification 63 T2DM 63 chemoradiation 63 ischemia driven 63 neoplasms 63 mCRC patients 63 grade dysplasia 63 parathyroidectomy 63 neoadjuvant radiation 63 CI #.#-#.# [001] 63 subclinical hyperthyroidism 63 System IPSS 63 gadolinium enhancing lesions 63 morphometric vertebral fractures 63 lactate dehydrogenase LDH 63 severe neutropenia 63 lactate dehydrogenase 63 cancer mCRC 63 cytogenetic response 63 OGTT 63 medically inoperable 63 TP# mutations 63 serum calcium 63 postoperatively 63 myocardial ischemia 63 recurrent glioblastoma multiforme 63 endoleak 63 Kaplan Meier curve 63 p = #.# [004] 63 NNRTI resistance 63 patients undergoing CABG 63 mCRPC 63 glomerular filtration 63 axillary nodes 63 DAS# scores 63 subclinical hypothyroidism 63 ejection fractions 63 resected pancreatic cancer 63 Postoperative 63 timepoint 63 squamous histology 63 NYHA class 63 scintigraphic 63 CIN3 + 63 premalignant lesions 63 lobular carcinoma 62 lung metastases 62 creatinine ratio 62 systolic dysfunction 62 troponins 62 immunostaining 62 TEAEs 62 Multivariate analysis 62 TAXUS Express Stent 62 logistic regression analyzes 62 histopathologic examination 62 cTnT levels 62 serum calcium levels 62 thromboembolic 62 HER2 overexpression 62 situ LCIS 62 transvaginal sonography 62 HBeAg 62 obstructive CAD 62 metastases 62 EUS FNA 62 adenoma detection 62 plasma uric acid 62 % CI #.#-#.# [005] 62 complete cytogenetic response 62 graft occlusion 62 multivariate adjustment 62 Rectal cancer 62 tertiles 62 diameter stenosis 62 HER2 positive metastatic breast 62 metastatic GIST 62 colorectal polyp 62 haematologic 62 Index CDAI 62 parenchymal 62 allogeneic SCT 62 comorbidity 62 pheochromocytoma 62 multivariate analysis 62 hormone receptor status 62 comorbidities 62 RECIST Response Evaluation Criteria 62 cytogenic 62 cerebrovascular events 62 BRCA1 mutation carriers 62 revascularization procedure 62 abnormal cytology 62 HDRS 62 Preoperatively 62 multivariable logistic regression 62 serum cortisol 62 Circulating tumor cells 62 taxane therapy 62 IFN α 62 cervical intraepithelial neoplasia 62 -#.# ± [002] 62 lymphocyte count 62 sirolimus eluting stents 62 QTc prolongation 62 elevated ALT 62 postprocedure 62 RECIST criteria 62 metastatic prostate cancer 62 transrectal ultrasound guided 62 androgen ablation 62 interquartile range 62 monoclonal gammopathy 62 sonographically 62 FDG PET imaging 62 rheumatoid factor 62 epithelial ovarian cancer 62 serum thyroglobulin 62 Univariate analysis 62 nonoperative 62 pathologic diagnosis 62 CsA 62 Median PFS 62 seminomas 62 FOLFIRI 62 infarct size 62 neoplasias 62 adjuvant cisplatin 62 HIV HCV coinfected 62 renal cell carcinomas 62 Adjuvant chemotherapy 62 bilateral oophorectomy 62 receiving VICTRELIS 62 prospectively stratified 62 salpingo oophorectomy 62 metastatic gastric 62 endoscopic ultrasonography 62 lung resections 62 total thyroidectomy 62 poorer prognosis 62 atrioventricular block 62 clinicopathologic 62 Breslow thickness 62 clinically insignificant 62 histopathologic 62 serum urate levels 62 SHBG levels 62 antiangiogenic therapy 62 cervical lymph nodes 62 mIU L 62 mIU ml 62 angiographic outcomes 62 adjunctive placebo 62 baseline FEV 62 serum ALT 62 nonobese 62 ductal cancer 62 serum HBV DNA 62 Cystectomy 62 comorbid conditions 62 colectomy 62 invasive coronary angiography 62 total knee arthroplasty 62 achieved ACR# 62 thrombocytopenic 62 resected tumors 62 hydroxyvitamin D levels 62 estimated GFR 62 antithrombotic therapy 62 undergo prostate biopsy 62 subclinical atherosclerosis 62 Follicular Lymphoma 62 IPSS 62 undergoing coronary angiography 62 neoadjuvant treatment 62 postoperative complications 62 retroperitoneal 62 duplex ultrasonography 62 serum urate 62 MitraClip device 62 resection 62 breast carcinomas 62 NSTE ACS 62 B7 H3 62 CrCl 62 serum phosphate 62 covariate 62 seropositivity 62 node dissection 62 prednisone prednisolone 62 remission CR 62 #Gy 62 neurologic progression 62 XELOX 62 seminoma 62 tracer uptake 62 renal cysts 62 locoregional disease 62 BEACOPP 62 PSA velocity 62 oral anticoagulation 62 EGFR TKI 62 STRIDE PD 62 multivessel disease 62 ADPKD 62 cytologic 62 liver metastases 62 CHD mortality 62 prognostic indicators 62 pelvic lymph node dissection 62 extracolonic findings 62 NNT = 62 hemoglobin A1c levels 62 echocardiographic parameters 62 Hurthle cell 62 CC genotype 62 laparoscopic radical prostatectomy 62 periprocedural MI 62 tumor progression TTP 61 baseline HbA1c 61 D dimer 61 mutated K ras 61 thromboembolism 61 aortic insufficiency 61 Secondary endpoints include 61 thyrotropin levels 61 TIMP 61 TOP2A 61 Ishak fibrosis score 61 primary patency 61 urolithiasis 61 HRCT 61 postoperative AF 61 serum clusterin levels 61 vaginal hysterectomy 61 lymphopenia 61 hemodynamically significant 61 LV ejection fraction 61 VATS lobectomy 61 affective psychosis 61 atypia 61 neutrophil count 61 left ventricular LV 61 prostate cancer CRPC 61 invasive carcinoma 61 serum PTH 61 SVR# 61 osteopenic 61 leiomyomas 61 Secondary endpoints 61 μg dL 61 N telopeptide 61 clinico pathological 61 resections 61 carotid endarterectomy 61 minimally symptomatic 61 evaluable subjects 61 antigen PSA levels 61 hemorrhagic complications 61 doxorubicin docetaxel 61 endometrial hyperplasia 61 serous ovarian cancer 61 revascularizations 61 warfarin therapy 61 HER2 positive cancers 61 pamidronate 61 systemic embolism 61 mutated KRAS 61 Recurrence 61 noninferiority 61 invasive lobular 61 prospective multicenter study 61 core needle biopsy 61 ABCB1 61 transesophageal echocardiography 61 events MACE 61 mediastinal lymph nodes 61 TACE 61 OPCAB 61 evaluable 61 hormone receptor negative 61 CK MB 61 varicocele 61 myocardial reperfusion 61 endarterectomy 61 cervical carcinoma 61 placebo dexamethasone 61 WOMAC pain 61 β blockers 61 symptomatic intracranial hemorrhage 61 p = #.# [002] 61 preoperative 61 epithelial ovarian 61 CYP#D# inhibitor 61 hyperintense lesions 61 hydronephrosis 61 QoL 61 metastatic castration resistant 61 relapsed AML 61 occult metastases 61 CYP#D# genotype 61 morphologic 61 kidney allograft 61 TKAs 61 carotid endarterectomy CEA 61 Target Lesion Revascularization TLR 61 nonsignificant 61 gadolinium enhancing 61 neoplastic lesions 61 nonvertebral fractures 61 endometrial cancers 61 atherothrombotic disease 61 prespecified 61 paroxysmal AF 61 IV bisphosphonates 61 recurrent DVT 61 laboratory abnormalities 61 #mmHg [001] 61 LHRH agonists 61 undergoing radical cystectomy 61 disease progression 61 hemodialysis patients 61 coronary artery stenosis 61 invasive angiography 61 F FDG uptake 61 telomere lengths 61 wedge resection 61 elevated transaminases 61 elevated IOP 61 heterozygotes 61 serum aminotransferase levels 61 tamoxifen therapy 61 stent implantation 61 elevated CRP 61 systolic BP 61 acetabular fractures 61 autonomic dysfunction 61 Heavy menstrual bleeding 61 catheter angiography 61 adjuvant tamoxifen 61 tumor necrosis 61 recurrent NSCLC 61 prespecified secondary 61 hepatic lesions 61 thrombotic complications 61 Folfox 61 antithymocyte globulin 61 pancreatic carcinoma 61 HbA1C 61 antiretroviral naïve 61 APACHE II 61 cerebral angiography 61 endocrine therapies 61 sentinel nodes 61 alanine aminotransferase 61 pathologic fractures 61 intraoperative complications 61 thyroidectomy 61 immunohistochemical 61 oblimersen 61 urothelial cancer 61 EpCAM expression 61 pulmonary nodules 61 Lymph node 61 heavily pretreated 61 TNM staging 61 K ras mutations 61 TT genotype 61 everolimus eluting stents 61 nonresponders 61 Kaplan Meier estimate 61 stenoses 61 liver biopsies 61 hepatorenal syndrome 61 BRAF V#E mutation 61 cystoscopic 61 serum creatinine 61 interobserver agreement 61 metastatic malignant 61 EGFR mutation positive 61 immunohistochemical staining 61 peritumoral 61 TRUS biopsy 61 HoLEP 61 recurrent ischemia 61 Solid Tumors RECIST 61 hypervascular 61 ERCC1 61 Baseline characteristics 61 ximelagatran 61 serum IGF 61 fibrinolytic therapy 61 erythrocyte sedimentation rate 61 neutrophil counts 61 adenomas 61 cisplatin vinorelbine 61 Scale EDSS 61 peritoneal cancer 61 incomplete revascularization 61 gastric carcinoma 61 CABG surgeries 61 DAS# remission 61 target vessel revascularization 61 5FU 61 metabolic parameters 61 decompensated cirrhosis 61 DAS# [002] 61 tHcy 61 euthyroid 61 #ng/ml 61 tirofiban 61 brain metastases 61 fragility fracture 61 ANCOVA 61 RYGB 61 dose dexamethasone 61 serum estradiol 61 Immunohistochemical staining 61 oral clodronate 61 sarcomatoid 61 creatinine clearance 61 neointimal hyperplasia 61 allogeneic stem cell 61 prostate TURP 61 percutaneous biopsy 61 TIMP 1 61 pulmonary dysfunction 61 NSTEMI 61 prostatic hyperplasia 61 endoscopic remission 61 DMARD 61 atypical ductal hyperplasia 61 intrahepatic 61 peritoneal carcinomatosis 61 colonic polyps 61 gastric cardia 61 poor metabolizers 61 myocardial infarction 61 systolic function 61 Kaplan Meier survival 61 neurologic complications 61 adjuvant hormonal therapy 61 FDG PET CT 61 cellularity 61 colorectal metastases 61 μg L 61 hematuria 61 Preoperative 61 pulmonary artery banding 61 Events MACE 61 invasive carcinomas 61 infarcts 61 bortezomib refractory 61 Adenomas 61 recurrent GBM 61 systolic hypertension 61 chemoembolization 61 neurocognitive function 61 myeloablative 61 papillary 61 sirolimus stent 61 malignant nodules 61 elevated troponin 61 BRCA mutation carriers 61 carotid intima media 61 depressive symptomatology 61 subgroup analyzes 61 postdischarge 61 unresectable 61 serum CRP 61 lipid lowering therapy 61 glycosylated hemoglobin HbA1c 61 tumor regressions 60 wound dehiscence 60 varices 60 oral Hycamtin 60 hemodilution 60 CLL SLL 60 stage IIIA 60 serum phosphate levels 60 postmenopausal osteoporotic women 60 interobserver 60 Bonferroni correction 60 lumbar disc herniation 60 nonischemic 60 postoperative radiographs 60 small lymphocytic lymphoma 60 colonoscopic 60 CP CPPS 60 estrogen receptor ER 60 corrected QT interval 60 antigen PSA 60 histologic findings 60 uveal melanoma 60 metastatic lung cancer 60 Crohn Disease Activity 60 CRp 60 Ejection Fraction 60 dichotomized 60 left ventricular systolic 60 mesotheliomas 60 nmol liter 60 odds ratios ORs 60 Postoperative complications 60 Thal Dex 60 left ventricular dysfunction 60 invasive aspergillosis 60 polypoid 60 sonographic findings 60 recurrent ischemic stroke 60 HCV genotype 60 CMV disease 60 HBeAg negative patients 60 intratumoral 60 disease progression TTP 60 leukemia AML 60 eosinophil count 60 oxycodone CR 60 transabdominal 60 hypogonadal 60 malignant lymphoma 60 variceal bleeding 60 serum lipid levels 60 lesional